Anti-Human APP/Amyloid beta Antibody (22D12)

Anti-Human APP/Amyloid beta Antibody (22D12)

  • Catalog number: RA14054
  • Availability: In Stock
  • $191.00

  • Ex Tax: $191.00


Available Options

Qty

Description: Anti-Human APP/Amyloid beta Antibody (22D12) [22D12] (RA14054) is a mouse monoclonal antibody detecting S-APP-beta in ELISA. Suitable for Human.
Host species: Mouse
Isotype: IgG2a, kappa
Species reactivity: Human
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: ELISA
Target: AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi).
References:
1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 25122912
2. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 17062754
3. Seamster, PE. et al. (2012) Physical biology 9, 055005. PMID: 23011729
Note: For research use only.

Images

  • SDS-PAGE for Anti-Human APP/Amyloid beta Antibody (22D12)
    SDS-PAGE

    SDS-PAGE for Anti-Human APP/Amyloid beta Antibody (22D12)

Be the first to write a review for this product.

Write a review

Note: HTML is not translated!
Bad           Good